atypical antipsychotic agent

atypical antipsychotic agent

a functional category of newer antipsychotic drugs thought to exert their action predominantly through serotonergic blockade; now frequently called second-generation antipsychotics.

a·typ·i·cal an·ti·psy·chot·ic a·gent

(ā-tip'i-kăl an'tē-sī-kot'ik ā'jĕnt)
A functional category of newer antipsychotic drugs (e.g., olanzapine, clozapine) thought to exert their action predominantly through serotonergic blockade.
References in periodicals archive ?
Sumitomo Dainippon Pharma") (Head Office: Osaka, Japan: President: Masayo Tada) and Takeda Pharmaceutical Company Limited ("Takeda") (Head Office: Osaka, Japan: President and CEO: Christophe Weber) today jointly announced that their license agreement entered into in March 2011 ("Agreement") for the joint development and exclusive commercialization of pharmaceutical products containing lurasidone hydrochloride (Latuda), an atypical antipsychotic agent, in Europe, will be terminated.
announced that they have entered into a license agreement for the commercialization of lurasidone hydrochloride ("lurasidone"), an atypical antipsychotic agent discovered by DSP, in Brazil and Venezuela.
This atypical antipsychotic agent, which was used in the study at a mean daily dose of just 7.
Risperidone tablets are an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults and adolescent aged 13-17 years alone, or in combination with lithium or valproate, for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults, and alone in children and adolescent aged 10-17 years, and also for the treatment of irritability associated with autistic disorder in children and adolescents aged 5-16 years.
Indianapolis, IN) is an atypical antipsychotic agent effective for treatment of psychosis and behavioral conditions in the elderly.
Moreover, concomitant therapy with an atypical antipsychotic agent did not necessarily protect against an increase in anxiety in the 134-patient study.
Food and Drug Administration (FDA) for lurasidone, an investigational atypical antipsychotic agent for the treatment of schizophrenia.
Risperidone (Risperdal), an atypical antipsychotic agent manufactured by Janssen Pharmaceutica, is approved for adults with schizophrenia or acute manic or mixed episodes.
Risperidone is an atypical antipsychotic agent indicated for the acute and maintenance treatment of schizophrenia in adults and alone, or in combination with lithium or valproate, for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults.
POSTER NR507 - A Pharmacokinetic (PK)-Pharmacodynamic (PD) Relationship Exists for Efficacy of Iloperidone, a Novel Investigational Atypical Antipsychotic Agent (Paolo Baroldi, M.
Sunovion) today announced that Latuda([R])(lurasidone HCl) tablets, a once-daily atypical antipsychotic agent indicated for the treatment of adult patients with schizophrenia, is now available by prescription in pharmacies across the United States and Puerto Rico.